| Autor: |
О. B. Kalashnikova, M. O. Ivanova, N. P. Volkov, E. V. Kondakova, E. A. Izmailova, I. M. Barhatov, T. L. Gindina, E. V. Babenko, A. D. Kulagin, N. B. Mikhailova, I. S. Moiseev |
| Jazyk: |
ruština |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, Vol 27, Iss 3, Pp 80-96 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1607-4181 |
| DOI: |
10.24884/1607-4181-2020-27-3-80-96 |
| Popis: |
Introduction.The biological heterogeneity of chronic lymphocytic leukemia (CLL) is reflected in the rate of progression, the need for therapy, and the response to treatment. Analysis of prognostic factors contributes to improving the quality of treatment and rational distribution of healthcare resources.Materials and methods. Among 890 patients with documented stage of CLL, 405 (45.5 %) received treatment. As the first-line of treatment, 173 patients received intensive regimens (FCR or BR), 6 – new agents, and 226 – all other regimens. The initial stage of the disease, mutation status of IGHV, del17p with or without complex karyotype were analyzed as prognostic markers.Results. Immunochemotherapeutic regimens were shown to be highly effective in case planned amount of treatment was completed. The combination of such prognostic parameters as the initial stage of the disease, the mutation status of IGHV, and the presence of del17p and/or complex karyotype allows us to clearly identify a group of patients with an unfavorable prognosis, for which it is advisable to use either intensive programs or new agents in the first-line therapy. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
